NAM
LGND icon

Nichols Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Nichols Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-148,135
Closed -$9.9M – 86
2016
Q1 		$9.9M Sell
148,135
-1,217
-0.8% -$74K 2.18% 12
2015
Q4 		$10.1M Sell
149,352
-411
-0.3% -$25.4K 2.2% 12
2015
Q3 		$8M Sell
149,763
-13,680
-8% -$830K 1.79% 35
2015
Q2 		$10.3M Sell
163,443
-88,247
-35% -$4.81M 1.84% 12
2015
Q1 		$12.1M Buy
251,690
+15,312
+6% +$587K 2.12% 4
2014
Q4 		$7.85M Buy
236,378
+22,589
+11% +$735K 1.54% 37
2014
Q3 		$6.27M Buy
213,789
+4,783
+2% +$159K 1.29% 51
2014
Q2 		$8.12M Buy
+209,006
New +$8.48M 1.64% 24

Other funds holding LGND

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Nichols Asset Management's LGND Position: Q2 2016 in Review

Nichols Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2016, closing a stake of 148,135 shares — an estimated $9.9M sold.

Nichols Asset Management first reported a position in LGND in Q2 2014 and held it in 8 quarters. The position peaked at $12.1M in Q1 2015. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2016.

  • Nichols Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Nichols Asset Management sold 148,135 Ligand Pharmaceuticals shares in Q2 2016, an estimated $9.9M.
  • Nichols Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 8 quarters.
  • Nichols Asset Management's Ligand Pharmaceuticals position peaked at $12.1M in Q1 2015.
  • 265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2016.

Based on Nichols Asset Management's 13F filing for Q2 2016, filed 5 Aug 2016.